

Effects of radiotherapy on olfactory function in patients with head and neck cancer

Submission date 28/09/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/09/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/02/2026	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Head and neck cancer patients often receive radiotherapy as part of their treatment. While radiotherapy is effective in controlling cancer, it can also affect nearby structures, including the olfactory system. Loss of smell may reduce quality of life, but little is known about how radiotherapy dose to the olfactory region relates to long-term changes in smell function. This study aims to determine how many patients developed olfactory dysfunction after radiotherapy, and whether higher radiation doses were associated with a greater risk of smell loss. Secondary analyses explore changes in the Taiwan Smell Identification Test (TWSIT), a standardised smell test, scores over time, dose-response relationships, and potential threshold doses predictive of olfactory dysfunction.

Who can participate?

Adult patients with head and neck cancer who were scheduled for intensity-modulated radiotherapy (IMRT) at Chang Gung Memorial Hospital, Chiayi, Taiwan.

What does the study involve?

Participants were prospectively enrolled between January 2021 and December 2023. All participants completed the TWSIT, a standardised smell test, before treatment and again after radiotherapy at 1, 3, 6, and 12 months. Radiation dose to the olfactory structures was measured from radiotherapy treatment plans.

What are the possible benefits and risks of participating?

By clarifying the relationship between radiation dose and olfactory outcomes, this study may help doctors to better predict, explain, and potentially reduce smell-related side effects of head and neck cancer treatment in the future.

No risks provided at registration

Where is the study run from?

Chang Gung Memorial Hospital, Chiayi, Taiwan.

When is the study starting and how long is it expected to run for?
November 2020 to December 2023

Who is funding the study?
Chang Gung Medical Foundation, Taiwan.

Who is the main contact?
Dr Geng He Chang, genghechang@gmail.com

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Geng He Chang

ORCID ID

<https://orcid.org/0000-0001-5939-9747>

Contact details

No.8, W. Sec., Jiapu RD., Puzi City
Chiayi
Taiwan
61363
+886-5-3621000 ext.2076
genghechang@gmail.com

Additional identifiers

Protocol serial number

Funding grant number CMRPG6L0041-3

Study information

Scientific Title

Prospective observational cohort study of radiotherapy dose to the olfactory region and subsequent olfactory dysfunction in head and neck cancer patients at Chang Gung Memorial Hospital

Acronym

OLFACT-RT

Study objectives

To investigate the relationship between radiation dose delivered to the olfactory region and the occurrence of olfactory dysfunction in patients with head and neck cancer receiving intensity-modulated radiotherapy (IMRT).

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 27/11/2020, Chang Gung Medical Foundation Institutional Review Board (199 Tung Hwa North Road, Taipei, 10507, Taiwan; +886-3-3196200 ext.3705; tsengshui@cgmh.org.tw), ref: 202001923B0C501

Study design

Prospective observational cohort study single-centre study

Primary study design

Observational

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Head and neck cancers (including nasopharyngeal carcinoma, nasal cavity cancer, oral cavity cancer, tonsil cancer, hypopharyngeal cancer, laryngeal cancer, parotid cancer and palate cancer)

Interventions

All participants received standard-of-care intensity-modulated radiotherapy (IMRT), with some patients also receiving concurrent chemotherapy as clinically indicated. No additional interventions were assigned by the investigators.

Intervention Type

Procedure/Surgery

Primary outcome(s)

The proportion of participants with olfactory dysfunction (TWSIT <40) measured using the Taiwan Smell Identification Test (TWSIT, score range 0–48) at baseline (pre-RT), end of radiotherapy, and at 1, 3, 6, and 12 months post-RT

Key secondary outcome(s)

1. Change in olfactory function measured using the change in TWSIT scores (continuous 0–48) from baseline to end of RT and to 1, 3, 6, and 12 months post-RT
2. Dose–response relationship measured using the association between mean olfactory-region radiation dose (Gy) and change in TWSIT scores measured using radiotherapy treatment plans at one timepoint
3. Dose threshold exploration measured using the identification of potential radiation dose cut-off values predictive of olfactory dysfunction using ROC analysis, measured using radiotherapy treatment plans at one timepoint
4. Regression analysis of odds measured using the logistic regression analysis of odds of post-RT olfactory dysfunction in relation to olfactory-region dose, adjusted for relevant covariates measured using radiotherapy treatment plans at one timepoint

Completion date

31/12/2023

Eligibility

Key inclusion criteria

1. Patients with histologically confirmed head and neck cancer scheduled for curative intensity modulated radiotherapy (IMRT) at Chang Gung Memorial Hospital
2. Provided written informed consent approved by the Chang Gung Medical Foundation IRB

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

63

Key exclusion criteria

1. Severe nasal septal deviation with hypertrophic turbinate
2. Chronic rhinosinusitis with or without nasal polyps
3. History of head trauma
4. Prior radiotherapy to the head and neck region
5. Baseline olfactory dysfunction defined as Taiwan Smell Identification Test (TWSIT) score <40

Date of first enrolment

12/01/2021

Date of final enrolment

17/11/2023

Locations**Countries of recruitment**

Taiwan

Study participating centre

Chang Gung Memorial Hospital, Chiayi Branch

8, Sec. West Jiapu Road, Puzi City

Chiayi

Taiwan
61363

Sponsor information

Organisation

Chang Gung Memorial Hospital

ROR

<https://ror.org/02verss31>

Funder(s)

Funder type

Research organisation

Funder Name

Chang Gung Medical Foundation

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Taiwan

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication. Individual participant data (IPD) will not be shared due to ethical and privacy restrictions. Only aggregated results will be reported in publications and presentations.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type
[Results article](#)

Details

Date created
01/12/2025

Date added
04/02/2026

Peer reviewed?
Yes

Patient-facing?
No